Vaqta is an inactivated whole virus vaccine derived from hepatitis A virus grown in cell culture in human MRC-5 diploid fibroblasts. It contains inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain.
The virus is grown, harvested and purified by a combination of physical and high performance liquid chromatographic techniques, formalin-inactivated, and then adsorbed onto aluminum hydroxide.
Vaqta is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older.
The primary dose should be given at least 2 weeks prior to expected exposure to HAV.
Vaqta is administered intramuscularly only.
- Children/Adolescents: vaccination consists of a 0.5-mL primary dose and a 0.5-mL booster dose 6 to 18 months later.
- Adults: vaccination consists of a 1-mL primary dose and a 1-mL booster dose 6 to 18 months later.
Hepatitis A virus has a relatively long incubation period (approximately 20 to 50 days). Vaqta may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination.